Short Interest in Cingulate Inc. (NASDAQ:CINGW) Drops By 36.0%

Cingulate Inc. (NASDAQ:CINGW) was the recipient of a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 735 shares, a drop of 36.0% from the July 15th total of 1,149 shares. Based on an average daily volume of 11,063 shares, the short-interest ratio is presently 0.1 days.

Cingulate Stock Performance

NASDAQ CINGW opened at $0.01 on Thursday. Cingulate has a 1 year low of $0.00 and a 1 year high of $0.12. The company has a fifty day moving average of $0.02 and a 200 day moving average of $0.03.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.